RecruitingNot ApplicableNCT07188233

Mitral Annular Repair With the CathHELIX™ Transcatheter System in Subjects With FMR

A Study to Evaluate the Feasibility and Safety of Mitral Annular Repair With the CathHELIX™ Transcatheter System in Subjects With Functional Mitral Regurgitation


Sponsor

HVR Cardio Oy

Enrollment

5 participants

Start Date

Nov 16, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Patients with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) will be evaluated for treatment using the CathHELIX Transcatheter Mitral Annuloplasty System.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Moderate to severe (3+) or severe (4+) functional mitral regurgitation
  • Left ventricular ejection fraction ≥30%
  • Symptomatic New York Heart Association (NYHA) Class II to IV).

Exclusion Criteria6

  • Oxygen dependent for COPD
  • Active or suspected endocarditis
  • Severe symptomatic carotid stenosis
  • Has undergone heart transplantation.
  • Severe calcification of the mitral annulus or leaflets
  • Coronary sinus anatomy that may preclude proper treatment with the device

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETranscatheter Mitral Valve Repair

Mitral valve repair with the CathHELIX Transcatheter Mitral Annuloplasty System in subjects with functional Mitral Regurgitation


Locations(2)

Tbilisi Heart and Vascular Clinic

Tbilisi, Georgia, Georgia

Vilnius University Hospital, Santaros Klinikos, Public Institution

Vilnius, Lithuania, Lithuania

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07188233


Related Trials